Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in indian patients

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 5, 2009, Pages 773-778

  Munjal, Kavita ^a   Ambaye, Abiy ^b   Evans, Mark F ^b   Mitchell, Jeannette ^b   Nandedkar, Shirish ^a   Cooper, Kumarasen ^b  

^a SRI AUROBINDO INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Er and pr; Her2; Immunohistochemistry; Invasive breast carcinoma; Molecular subtypes

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KRT5 PROTEIN, HUMAN; KRT6A PROTEIN, HUMAN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-5; KERATIN-6; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 77952297983     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Abd El-Rehim DM, Pinder SE, Paish CE et al (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol, 203, 661-71.
2. Abd El-Rehim DM, Ball G, Pinder SE et al (2005). Highthroughput protein expression analysis using tissue microarray technology of a large well-characterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer, 116, 340-50.
3. Ahr A, Karn T, Solbach C, et al (2002). Identification of high risk breast-cancer patients by gene expression profiling. Lancet, 359, 131-2.
4. Badwe RA, Mitra I, Desai PB (1990). Clinico-pathological features and prognosis of breast cancer in different religious communities in India. Indian J Cancer, 27, 220-229.
5. Carey LA, Perou CM, Livasy CA et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502.
6. Carey LA, Dees EC, Sawyer L, et al (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 13, 2329-34.
7. Eifel P, Axelson JA, Costa J, et al (2001). National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst, 93, 979-89.
8. Fan C, Oh DS, Wessels LAB, et al (2006). Concordance among gene-expression-based predictors for breast bancer. N Engl J Med, 355, 560-9.
9. Foekens JA, Atkins D, Zhang Y et al (2006). Multicenter validation of a gene expression-based prognostic signature in lymph node- negative primary breast cancer. J Clin Oncol, 24, 1665-71.
10. Foulkes WD, Stefansson IM, Chappuis PO, et al (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 95,1482-5.
11. Galea MH, Blamey RW, Elston CE, Ellis IO (1992). The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat, 22, 207-19.
12. Goldhirsch A, Wood WC, Gelber RD, et al (2003). Meeting highlights: updated international expert consensus on primary therapy of early breast cancer. J Clin Oncol, 21, 3357-65.
13. Huang E, Cheng SH, Dressman H, et al (2003). Gene expression predictors of breast cancer outcomes. Lancet, 361, 1590-6.
14. Indian Council of Medical Research. Biennial Report (1989). New Delhi, India.
15. Iwao K, Matoba R, Ueno N, et al (2002). Molecular classification of primary breast tumors possessing distinct prognostic properties. Hum Mol Genet, 11, 199-206.
16. Jacobs TW, Gown AM, Yaziji H, et al (1999), Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol, 17, 1983-7.
17. Livasy CA, Perou CM, Karaca G et al (2007). Identification of basal-like subtype of breast ductal carcinoma in situ. Human Pathology, 8, 197-204.
18. Ma XJ, Wang Z, Ryan PD, et al (2004). A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell, 5, 607-16.
19. Murthy NS, Juneja A, Sehgal A et al (1990). Cancer projection by the turn of the century - Indian scene. Ind J Cancer, 27, 74-82.
20. National Cancer registry Program. Ten year consolidated report of the Hospital Based Cancer Registries, 1984-1993. An assessment of the burden and care of cancer patients. Indian Council of Medical Research, New Delh (2001).
21. National Cancer registry Programme. Consolidated report of the population based cancer registries 1990-1996. Indian Council of Medical Research, New Delhi (2001).
22. Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74.
23. Olivotto IA, Bajdik CD, Ravdin PM, et al (2005). Populationbased validation of the prognostic model ADJUVANT! For early breast cancer. J Clin Oncol, 23, 2716-25.
24. Olopade OI, Grushko T (2001). Gene-expression profiles in hereditary breast cancer. N Engl J Med, 344, 2028-9.
25. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
26. Paik S, Shak S, Tang G, et al (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med, 351, 2817-26.
27. Saxena S, Rekhi B, Bansal A, et al (2007). Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India-A cross-sectional study. World J Surg Oncol, 3, 67.
28. Siddiqi M, Sen U, Mondal T, et al (2001). Cancer statistics from non-ICMR registries: Population based registries, CRAB (Cancer registry Abstract). Newsletter of the National Cancer Registry Project of India. pp. 47-59.
29. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci US A, 98, 10869-74.
30. Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100, 8418-23.
31. Sotiriou C, Neo SY, McShane LM, et al (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA, 100, 10393-8.
32. Van de Rijn M, Perou CM, Tibshirani R, et al (2002). Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol, 161, 1991-6.
33. Van de Vijver MJ, He YD, van't Veer LJ, et al (2002). A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med, 347, 1999-2009.
34. Van't Veer LJ, Dai H, van de Vijver MJ, et al (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-6.
35. Yang XR, Sherman ME, Rimm DL, et al (2007). Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev, 16, 439-43.